FDA Approves Velsipity (etrasimod) for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

NEW YORK--(BUSINESS WIRE) October 13, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Velsipity™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news